Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Makoto Maemondo

Prediction of ALK Mutations Mediating ALK-TKIs Resistance and Drug Re-Purposing to Overcome the Resistance

EBioMedicine

English

Three‐year Follow‐up Results From Phase II Studies of Nivolumab in Japanese Patients With Previously Treated Advanced Non‐small Cell Lung Cancer: Pooled Analysis of ONO‐4538‐05 and ONO‐4538‐06 Studies

English

Related publications

MA26.01 Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC

Journal of Thoracic Oncology

English

Molecular Mechanisms of Resistance to First- And Second-Generation ALK Inhibitors in ALK-rearranged Lung Cancer

European Journal of Cancer

Cancer Research

Oncology

2016

English

P3.08-18 Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed by EMT

Journal of Thoracic Oncology

English

P1.01-009 Clinically Primary and Secondary Resistance to ALK Inhibitors in ALK-Positive Advanced Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

English

Targeting Efflux Pumps to Overcome Antifungal Drug Resistance

Future Medicinal Chemistry

English

P1.13-07 Epithelial-Mesenchymal Transition Induced the Acquired Resistance to ALK Inhibitor Brigatinib in Lung Cancer Cells Harboring With ALK Fusions

Journal of Thoracic Oncology

English

Treatment of Acute Myeloid Leukemia Carrying Inv(2)(p23q13)/Ranbp2-Alk With Crizotinib and the Mechanism of Resistance to the Drug

Tenri Medical Bulletin

2015

English

EMT Is Associated With, but Does Not Drive Resistance to ALK Inhibitors Among EML4-ALK Non-Small Cell Lung Cancer

English

P1.01-67 Clinical Relevance of ALK/ROS1 Resistance Mutations and Other Acquired Mutations Detected by Liquid Biopsy in Advanced NSCLC Patients

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Makoto Maemondo

Prediction of ALK Mutations Mediating ALK-TKIs Resistance and Drug Re-Purposing to Overcome the Resistance

Three‐year Follow‐up Results From Phase II Studies of Nivolumab in Japanese Patients With Previously Treated Advanced Non‐small Cell Lung Cancer: Pooled Analysis of ONO‐4538‐05 and ONO‐4538‐06 Studies

Related publications

MA26.01 Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC

Molecular Mechanisms of Resistance to First- And Second-Generation ALK Inhibitors in ALK-rearranged Lung Cancer

P3.08-18 Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed by EMT

P1.01-009 Clinically Primary and Secondary Resistance to ALK Inhibitors in ALK-Positive Advanced Non-Small-Cell Lung Cancer

Targeting Efflux Pumps to Overcome Antifungal Drug Resistance

P1.13-07 Epithelial-Mesenchymal Transition Induced the Acquired Resistance to ALK Inhibitor Brigatinib in Lung Cancer Cells Harboring With ALK Fusions

Treatment of Acute Myeloid Leukemia Carrying Inv(2)(p23q13)/Ranbp2-Alk With Crizotinib and the Mechanism of Resistance to the Drug

EMT Is Associated With, but Does Not Drive Resistance to ALK Inhibitors Among EML4-ALK Non-Small Cell Lung Cancer

P1.01-67 Clinical Relevance of ALK/ROS1 Resistance Mutations and Other Acquired Mutations Detected by Liquid Biopsy in Advanced NSCLC Patients